Mikhail Blagosklonny is a professor of oncology at the Roswell Park Cancer Institute in New York. He holds a Ph.D. in experimental medicine and cardiology, as well as an M.D. in internal medicine, both of which he earned from the First Pavlov State Medical University of St. Petersburg.
At the beginning of his career in 2002, he held a position at the New York Medical College, where he worked until moving on to become a senior scientist at the Ordway Research Institute on Google. Finally, in 2009, he was appointed to the role of Professor of Oncology at the Roswell Park Cancer Institute, a job that he is currently still entertaining.
In addition to upholding his role as a professor, Mikhail Blagosklonny is a scientist who actively researches cancer and cancer therapies that damage sick cells while protecting healthy ones. As well, he is studying anti-aging and anti-aging treatments.
During his research on anti-aging, Mikhail Blagosklonny found a connection between a protein called mTOR, otherwise known as rapamycin, and anti-aging. Blagosklonny hypothesized that by using rapamycin in anti-aging drugs, life could be extended. Mr. Blagosklonny is considered to be one of the most dedicated scientists in the long-term study of mTOR and its potentially beneficial medical usages.
While his educational and professional achievements are certainly impressive, Mikhail Blagosklonny does even more still to help the medical and scientific community in learning about diseases and treatments in his chosen fields. He does this by serving as the editor-in-chief of several weekly and monthly peer-review open access medical journals. In these scientific journals on researchgate.net, titled, “Aging,” “Cell Cycle,” and “Oncotarget,” the subjects of aging, cell biology, and oncology are explored in depth.
With the implementation of his peer-review editorials on LinkedIn and his recent breakthrough anti-aging hypothesis, it is impossible to envision a future without Mikhail Blagosklonny furthering his attempts to not only extend our lives but to cure our most deadly of diseases as well.